Wells Fargo’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-25
Closed – – 7787
2020
Q4
$0 Hold
25
– – ﹤0.01% 7449
2020
Q3
$0 Sell
25
-1
-4% -$5 ﹤0.01% 7342
2020
Q2
$0 Hold
26
– – ﹤0.01% 7256
2020
Q1
$0 Buy
+26
New +$188 ﹤0.01% 7284
2017
Q3
– Sell
-14
Closed – – 6575
2017
Q2
$0 Hold
14
– – ﹤0.01% 6586
2017
Q1
$0 Hold
14
– – ﹤0.01% 6634
2016
Q4
$1K Hold
14
– – ﹤0.01% 6203
2016
Q3
$0 Hold
14
– – ﹤0.01% 6448
2016
Q2
$0 Hold
14
– – ﹤0.01% 6472
2016
Q1
$0 Hold
14
– – ﹤0.01% 6561
2015
Q4
$1K Hold
14
– – ﹤0.01% 6142
2015
Q3
$3K Buy
14
+4
+40% +$788 ﹤0.01% 5953
2015
Q2
$1K Buy
+10
New +$1.39K ﹤0.01% 6279

Other funds holding IDXG

Wells Fargo's IDXG Position: Q1 2021 in Review

Wells Fargo sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2021, closing a stake of 25 shares.

Wells Fargo first reported a position in IDXG in Q2 2015 and held it in 13 quarters. The position peaked at $3K in Q3 2015. 3 funds tracked by Wall St. Rank hold IDXG as of Q1 2021.

  • Wells Fargo reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Wells Fargo sold 25 Interpace Biosciences, Inc. Common Stock shares in Q1 2021.
  • Wells Fargo first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2015 and held it in 13 quarters.
  • Wells Fargo's Interpace Biosciences, Inc. Common Stock position peaked at $3K in Q3 2015.
  • 3 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2021.

Based on Wells Fargo's 13F filing for Q1 2021, filed 13 May 2021.